Yan Feng

Title: Innovations by Yan Feng: Pioneering KRAS Degrader Compounds

Introduction

Yan Feng is an accomplished inventor based in Plainsboro, NJ (US), known for her significant contributions to the field of biotherapeutics. With a total of three patents to her name, she has made remarkable strides in developing novel compounds aimed at treating diseases associated with KRAS mutations.

Latest Patents

Yan Feng's latest patents include groundbreaking work on glutarimide-containing pan-KRAS-mutant degrader compounds. The first patent focuses on novel pan-KRAS glutarimide-containing compounds that exhibit KRAS degradation activities. These compounds are formulated into pharmaceutical compositions that can be utilized in the prevention and treatment of various diseases and conditions. The second patent highlights glutarimide-containing KRAS-mutant degrader compounds, which also demonstrate degradation activities specific to the KRAS mutant form. This innovation further emphasizes the potential of these compounds in therapeutic applications.

Career Highlights

Yan Feng is currently associated with Tiger Biotherapeutics Inc., where she continues to advance her research and development efforts. Her work is pivotal in the ongoing quest to find effective treatments for conditions linked to KRAS mutations.

Collaborations

Some of her notable coworkers include Robert Luo and Pin Huang, who contribute to the collaborative environment that fosters innovation and research excellence.

Conclusion

Yan Feng's contributions to the field of biotherapeutics, particularly in the development of KRAS degrader compounds, showcase her innovative spirit and dedication to improving healthcare outcomes. Her work is a testament to the impact of scientific research on the treatment of complex diseases.